NCT01700049View on ClinicalTrials.gov

Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes

PHASE2CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

January 14, 2013

Primary Completion Date

July 3, 2017

Study Completion Date

July 3, 2018

Conditions

Basal Cell Carcinoma

Interventions

DRUG

vismodegib (150 mg PO daily)

Biopsies will be performed on all participants at baseline, week 12 and week 24.

Trial Locations (1)

63104

Saint Louis University Department of Dermatology, St Louis

Sponsors

Lead Sponsor

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Mayo Clinic

OTHER